BioVersys AG (SIX: BIOV), a clinical-stage biopharmaceutical company developing novel antibacterial treatments for serious infections caused by multi-drug resistant (MDR) bacteria, announced today that its management will present a corporate overview at the upcoming H.C. Wainwright 28th Annual Global Investment Conference. The conference is scheduled to take place September 14-16, 2026, in New York City.
Hernan Levett, Chief Financial Officer of BioVersys, will deliver a live presentation on September 16, 2026, from 12:30 PM to 1:00 PM ET at the Kennedy II room on the 4th floor of the Lotte New York Palace. Additionally, Dr. Marc Gitzinger, the company’s Chief Executive Officer, will provide an on-demand presentation starting September 11, 2026, at 7:00 AM ET, with a replay accessible for 90 days. The webcast will be available through the H.C. Wainwright platform and the BioVersys website in the investor section.
The announcement underscores BioVersys’ active engagement with the investment community as it advances its pipeline of antibacterial candidates. The company focuses on addressing the high unmet medical need for new treatments against life-threatening resistant bacterial infections, a growing global health concern. Their most advanced programs include BV100 for nosocomial infections caused by Acinetobacter baumannii, currently in Phase 3, and alpibectir for tuberculosis, in Phase 2, developed in collaboration with GlaxoSmithKline (GSK) and a consortium led by the University of Lille, France.
BioVersys leverages two proprietary technology platforms—TRIC and Ansamycin Chemistry—to design candidates that overcome resistance mechanisms, block virulence production, and directly affect the pathogenesis of harmful bacteria. This approach aims to provide new treatment options in the antimicrobial and microbiome fields, targeting not only resistant bacterial infections but also bacteria-exacerbated chronic inflammatory microbiome disorders.
The company’s participation in this prominent investment conference signals its commitment to keeping investors informed about its progress and strategic direction. With the rise of antimicrobial resistance posing a significant threat to public health, BioVersys’ efforts to develop innovative therapies are of critical importance. The presentations by both the CFO and CEO will offer insights into the company’s financial standing, pipeline advancements, and future outlook.
For registered attendees, one-on-one meetings with BioVersys’ CEO and CFO can be requested through their H.C. Wainwright representatives, providing an opportunity for in-depth discussions. The conference serves as a platform for BioVersys to highlight its potential to address urgent medical needs and to attract potential partners and investors.
BioVersys, headquartered in Basel, Switzerland, is dedicated to advancing its portfolio of antibacterial products. The company’s focus on multi-drug resistant bacteria aligns with global efforts to combat antimicrobial resistance, a priority for health organizations worldwide. By presenting at this conference, BioVersys aims to strengthen its visibility among investors and stakeholders, potentially facilitating further growth and collaboration.
The H.C. Wainwright conference is a key event for emerging growth companies, offering exposure to a wide range of investors. BioVersys’ participation underscores its proactive approach to investor relations and its confidence in its pipeline’s potential to make a significant impact on the treatment of serious infections.
